NCT01640834 is a Phase 1 clinical trial of LY2409021 in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.

Who is sponsoring NCT01640834?

NCT01640834 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT01640834?

Interventions in NCT01640834: LY2409021, Placebo, Glucagon.

What condition does NCT01640834 study?

NCT01640834 studies Diabetes Mellitus, Type 1.

Is NCT01640834 still recruiting?

NCT01640834 is currently completed. Last updated 24 March 2018.

Are results published for NCT01640834?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-03-24 · How we verify

NCT01640834

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus

Completed Phase 1 Results posted Last updated 24 March 2018

What this trial tests

Phase 1 trial testing LY2409021 in Diabetes Mellitus, Type 1 in 20 participants. Completed in 1 September 2012.

Timeline

1 July 2012

Primary endpoint
1 September 2012

1 September 2012

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	1 July 2012
Primary completion	1 September 2012
Estimated completion	1 September 2012
Sites	1 location across Germany

Drugs / interventions tested

LY2409021 — full drug profile →
Placebo
Glucagon (GLUCAGON) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose
Time frame: Baseline (Day 1), Day 2
The mean absolute change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.

Sponsor's own description

This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve screening within 30 days of the start of the study as well as telephone consultations within 5 days after discharge from the CRU.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Abstracts of the 49th EASD (European Association for the Study of Diabetes) Annual Meeting. September 23-27, 2013. Barcelona, Spain.
· 2013 · cited 3× · PMID 23949610 · DOI 10.1007/s00125-013-3012-z

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01640834 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 24 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01640834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing